Journal of psychopharmacology (Oxford, England)
December 26, 2025
Natalia Malikowska‐racia, Joanna Gołębiowska, Katarzyna Starowicz et al.
Ketamine, known for its rapid-acting antidepressant effects, is often coadministered with other psychoactive drugs, including opioids and cannabinoids, in both clinical and recreational settings. We investigated whether ketamine (R-, S-, or racemic R, S-) isoforms alter the subjective effects of morphine or Δ9-tetrahydrocannabinol (THC) and whether the interoceptive effects of ketamine overlap...
Journal of Psychopharmacology
October 16, 2023
Maciej Koniewski, Piotr Popik, Natalia Malikowska‐racia et al.
6 citations
Background: In clinical studies, psychedelics including psilocybin and D-lysergic acid diethylamide (LSD) demonstrate rapid and persistent antidepressant effects. Since the effective treatment with psychedelics is usually provided with psychotherapy, it is debatable whether their prolonged efficacy can be observed in infrahuman species. Preclinical reports on psychedelics’ effects most often...
Psychopharmacology
March 2, 2022
Piotr Popik, Adam S. Hogendorf, Ryszard Bugno et al.
30 citations
Time underestimation produced by (S)-ketamine could be associated with its antidepressant effects; however, it was accompanied with severe behavioral disruption. We also hypothesize that behavioral disruption produced by psychedelics objectively reflects their psychotomimetic-like actions.
Figshare
2021
Piotr Popik, Adam S. Hogendorf, Ryszard Bugno et al.
Dataset for the paper: Effects of ketamine optical isomers, psilocybin, psilocin and norpsilocin on time estimation and cognition in rats
Pharmacology, Biochemistry and Behavior
April 22, 2020
Jeffrey M. Witkin, J. Kranzler, K. Kaniecki et al.
33 citations
Substance abuse disorder continues to have devastating consequences for individuals and society and current therapies are not sufficient to provide the magnitude of medical impact required. Although some evidence suggests the use of ketamine in treating various substance use related- symptoms, its adverse event profile including dissociation, dysphoria, and abuse liability limit its potential...
European Journal of Pharmacology
August 8, 1996
Richard T. Layer, P Skolnick, C M Bertha et al.
48 citations
Based on both preclinical findings and anecdotal evidence in man, the psychoactive indole alkaloid ibogaine has been suggested to have anti-addictive properties. Previous studies indicate that blockade of NMDA receptors may mediate at least some of the putative anti-addictive actions of ibogaine. The potencies of a series of ibogaine analogs to inhibit...
Life Sciences
1996
Piotr Popik
18 citations
Anecdotal observations in humans indicate that indole alkaloid ibogaine may have anti-addictive properties. It has been suggested that the therapeutic action of ibogaine may depend upon facilitated access to the past experiences, purportedly influencing the initiation of drug addiction. To determine if ibogaine may facilitate memory retrieval, rats were trained in the Morris maze spatial...
Journal of Pharmacology and Experimental Therapeutics
November 1, 1995
Piotr Popik, Richard T. Layer, Linda H. Fossom et al.
100 citations
Both anecdotal reports in humans and preclinical studies indicate that ibogaine interrupts addiction to a variety of abused substances including alcohol, opiates, nicotine and stimulants. Based on the similarity of these therapeutic claims to recent preclinical studies demonstrating that N-methyl-D-aspartate (NMDA) antagonists attenuate addiction-related phenomena, we examined the NMDA...
Psychopharmacology
May 1, 1994
Piotr Popik, Richard T. Layer, P Skolnick
92 citations
Ibogaine is a putative anti-addictive drug with potential efficacy for the treatment of opiate, stimulant, and alcohol abuse. We now report ibogaine is a competitive inhibitor (Ki, 1.01 +/- 0.1 microM) of [3H]MK-801 binding to N-methyl-D-aspartate (NMDA) receptor coupled cation channels. Since MK-801 can attenuate the development of tolerance to morphine and alcohol as well as sensitization to...